LIFE BioCEEd has made another investment, supporting the development of a non-invasive and more accurate diagnostic method for multiple myeloma at the University Hospital in Hradec Králové.

A new diagnostic method is set to revolutionize the detection of multiple myeloma. Thanks to innovative technology, the diagnosis will be not only faster and less invasive but also up to six times more accurate, significantly improving patients’ lives. The first patients could start using this method as early as 2026.

Multiple myeloma is one of the most serious blood cancers, affecting approximately 4,000 people in the Czech Republic. “Current diagnostic methods, including immunofixation and bone marrow testing, have their limits, which significantly prolong the diagnostic process and subject patients to unpleasant and painful procedures,” explains Jakub Radocha, head of the research group at University Hospital Hradec Králové.

The new project, financed by the investment fund LIFE BioCEEd, which supports the development of advanced diagnostic methods, offers the opportunity for more accurate and patient-friendly testing that could be available starting in 2026.

This innovative diagnostic method is characterized by high sensitivity and speed, making it an ideal tool for the early detection of multiple myeloma. Unlike current methods, the new technology allows diagnosis through blood analysis, eliminating the need for painful bone marrow biopsies.

Preclinical results suggest that the accuracy of this method could be up to six times higher than current standard diagnostic tools. Early disease detection, improved monitoring of disease progression, and treatment efficacy will have a major impact on patient prognosis.

The new method also allows continuous monitoring, helping doctors and patients respond promptly to changes in the condition and adjust treatment accordingly.

“LIFE BioCEEd is committed to investing in potentially groundbreaking technologies that change the standard of care and significantly reduce patient suffering. The research at UH Hradec Králové fits this definition perfectly. Improving diagnostic methods is key — it brings more comfortable care and more precise results,” says Michal Zahradníček, co-founder of the fund.

This breakthrough in diagnostics aims not only to help patients with multiple myeloma but also to pave the way for further innovations in biotechnology and medicine.

Source: ČTK